CVX vs. LLY: Chevron vs. Eli Lilly Stock Comparison
How do Chevron (CVX) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Chevron (CVX) is classified in the Energy sector (Energy), whereas Eli Lilly (LLY) belongs to Health Care (Pharmaceuticals, Biotechnology & Life Sciences) — their GICS classifications point to very different parts of the market.
| Profile Item | CVX | LLY |
|---|---|---|
| Name | Chevron Corporation | Eli Lilly and Company |
| Country/Region | United States | United States |
| GICS Sector | Energy | Health Care |
| GICS Industry Group | Energy | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Oil, Gas & Consumable Fuels | Pharmaceuticals |
| GICS Sub-Industry | Integrated Oil & Gas | Pharmaceuticals |
| Market Capitalization | 414.86 billion USD | 1,206.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 1962 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CVX | LLY |
|---|---|---|
| Total Return (1Y) | 42.24% | 52.36% |
| Total Return (3Y, Annualized) | 19.22% | 34.18% |
| Total Return (5Y, Annualized) | 17.45% | 41.08% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CVX | LLY |
|---|---|---|
| Volatility (1Y, Annualized) | 24.66% | 35.34% |
| Beta (5Y) | 0.50 | 0.40 |
| Max Drawdown (5Y) | -24.95% | -34.48% |
| Avg. Volume (3M) | 8.39M | 2.52M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CVX | LLY |
|---|---|---|
| Sharpe Ratio (1Y) | 1.54 | 1.36 |
| Sortino Ratio (1Y) | 2.26 | 2.29 |
Profitability
ROE (TTM)
Eli Lilly (LLY) at 86.02% sits in the top ROE quartile, while Chevron (CVX) at 13.85% is closer to the peer norm — stronger capital efficiency for LLY.
CVX
Energy industry group
13.85%
- Max
- 53.85%
- Q3
- 24.79%
- CVX
- 13.85%
- Median
- 12.85%
- Q1
- 2.03%
- Min
- -29.09%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Eli Lilly (LLY) at 31.90% converts revenue to bottom-line profit above its industry’s benchmark range, while Chevron (CVX) at 11.92% keeps roughly the typical share for its industry.
CVX
Energy industry group
11.92%
- Max
- 56.92%
- Q3
- 22.92%
- CVX
- 11.92%
- Median
- 10.10%
- Q1
- 0.07%
- Min
- -27.38%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Eli Lilly (LLY) at 53.66% operates in the top operating margin quartile, ahead of Chevron (CVX) at 17.89%, which runs around its industry’s norm.
CVX
Energy industry group
17.89%
- Max
- 71.31%
- Q3
- 33.75%
- Median
- 18.73%
- CVX
- 17.89%
- Q1
- 6.94%
- Min
- -24.52%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
53.66%
- Max
- 83.12%
- LLY
- 53.66%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | CVX | LLY |
|---|---|---|
| ROE (TTM) | 13.85% | 86.02% |
| ROA (TTM) | 6.47% | 21.06% |
| Net Margin (TTM) | 11.92% | 31.90% |
| Operating Margin (TTM) | 17.89% | 53.66% |
| Gross Margin (TTM) | 44.39% | 83.63% |
Growth
Revenue Growth
Both Chevron (CVX) at -4.64% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Chevron (CVX) at -31.79% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | CVX | LLY |
|---|---|---|
| Revenue Growth (YoY) | -4.64% | 44.70% |
| Revenue Growth (3Y CAGR) | -7.85% | 31.69% |
| EPS Growth (YoY) | -31.79% | 95.99% |
| EPS Growth (3Y CAGR) | -28.69% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Chevron (CVX) at 1.34 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
CVX
Energy industry group
1.34
- Max
- 3.64
- Q3
- 2.21
- Median
- 1.41
- CVX
- 1.34
- Q1
- 0.88
- Min
- 0.24
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- LLY
- 1.39
- Min
- 0.10
Debt / Equity (MRQ)
Chevron (CVX) at 0.17 keeps leverage in the lower quartile, while Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile.
CVX
Energy industry group
0.17
- Max
- 1.75
- Q3
- 0.93
- Median
- 0.54
- Q1
- 0.30
- CVX
- 0.17
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.42
- LLY
- 1.23
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CVX | LLY |
|---|---|---|
| Current Ratio (MRQ) | 1.34 | 1.39 |
| Debt / Equity (MRQ) | 0.17 | 1.23 |
| Net Debt / EBITDA | 0.36 | 0.96 |
Dividends
Dividend Yield (TTM)
Chevron (CVX) at 3.31% pays an industry-typical yield; Eli Lilly (LLY) at 0.49% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.
CVX
Energy industry group
3.31%
- Max
- 8.57%
- Q3
- 3.58%
- CVX
- 3.31%
- Median
- 1.71%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.49%
- LLY
- 0.49%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Chevron (CVX) at 51.76% keeps its payout in the industry’s typical band, while Eli Lilly (LLY) at 21.71% pays out more than any of its peers — the most stretched cover in its group.
CVX
Energy industry group
51.76%
- Max
- 133.24%
- Q3
- 53.31%
- CVX
- 51.76%
- Median
- 25.24%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CVX | LLY |
|---|---|---|
| Dividend Yield (TTM) | 3.31% | 0.49% |
| Dividend Payout Ratio (TTM) | 51.76% | 21.71% |
Valuation
P/E Ratio (TTM)
Chevron (CVX) at 15.61 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.
CVX
Energy industry group
15.61
- Max
- 39.54
- Q3
- 21.72
- CVX
- 15.61
- Median
- 12.19
- Q1
- 7.71
- Min
- 2.99
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.95
- Max
- 85.34
- LLY
- 43.95
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Chevron (CVX) at 1.83 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
CVX
Energy industry group
1.83
- Max
- 5.40
- Q3
- 2.85
- CVX
- 1.83
- Median
- 1.69
- Q1
- 0.88
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.95
- Max
- 58.18
- Q3
- 25.77
- LLY
- 13.95
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Chevron (CVX) at 2.13 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.
CVX
Energy industry group
2.13
- Max
- 4.21
- Q3
- 2.38
- CVX
- 2.13
- Median
- 1.51
- Q1
- 1.08
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.96
- LLY
- 29.96
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | CVX | LLY |
|---|---|---|
| P/E Ratio (TTM) | 15.61 | 43.95 |
| P/S Ratio (TTM) | 1.83 | 13.95 |
| P/B Ratio (MRQ) | 2.13 | 29.96 |
| Free Cash Flow Yield (TTM) | 6.28% | 0.77% |